Procalcitonin and antibiotic use: imperfect, yet effective

The Lancet Infectious Diseases

Volumn 18, Issue 1, 2018, Pages 11-13

  Fontela, Patricia S ^a,b,c   Papenburg, Jesse ^a,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HYPERTENSION; MICROFLORA; MORTALITY; NOTE; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TREATMENT FAILURE; VIRAL RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CALCITONIN; HUMANS; PROCALCITONIN; RESPIRATORY TRACT INFECTIONS;

EID: 85031330902     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30593-5     Document Type: Note

References (16)

1. GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis, 2017 published online Aug 23. http://dx.doi.org/10.1016/S1473-3099(17)30396-1.
2. Shapiro, DJ, Hicks, LA, Pavia, AT, Hersh, AL, Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 69 (2014), 234–240.
3. Jain, S, Self, WH, Wunderink, RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 373 (2015), 415–427.
4. Chastre, J, Wolff, M, Fagon, JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290 (2003), 2588–2598.
5. Guillemot, D, Carbon, C, Balkau, B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279 (1998), 365–370.
6. Llewelyn, MJ, Fitzpatrick, JM, Darwin, E, et al. The antibiotic course has had its day. BMJ, 358, 2017, j3418.
7. Fontela, PS, Lacroix, J, Procalcitonin: is this the promised biomarker for critically ill patients?. J Pediatr Intensive Care 5 (2016), 162–171.
8. Reynolds, SC, Shorr, AF, Muscedere, J, Jiang, X, Heyland, DK, Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 40 (2012), 2781–2787.
9. Schuetz, P, Müller, B, Christ-Crain, M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev, 9, 2012 CD007498.
10. Schuetz, P, Wirz, Y, Sager, R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis, 2017 published online Oct 13. http://dx.doi.org/10.1016/S1473-3099(17)30592-3.
11. Ferrer, R, Martin-Loeches, I, Phillips, G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42 (2014), 1749–1755.
12. Gaieski, DF, Mikkelsen, ME, Band, RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38 (2010), 1045–1053.
13. Fontela, PS, Quach, C, Karim, ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 18 (2017), e395–e405.
14. Fontela, PS, Dagenais, M, Gaudreault, J, et al. Clinical reasoning behind antibiotic use in pediatric intensive care units: a qualitative study. 8th World Congress on Pediatric Intensive and Critical Care; Toronto, Canada; June 4–8, 2016. Abstract PICC-0731. http://www.picc2016.com/PublishingImages/scientific-information-abstracts/scientific-program/PICC 2016 posters abstracts all.pdf (accessed Oct 1, 2017).
15. Cremieux, AC, Muller-Serieys, C, Panhard, X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Antimicrob Agents Chemother 47 (2003), 2030–2035.
16. van Bijnen, EME, Paget, J, de Lange-de Klerk, ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One, 10, 2015, e0135094.